Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

H1N1 Infection Reduces Glucose Level in Human U937 Monocytes Culture.

Motawi TK, Shahin NN, Maghraby AS, Kirschfink M, Abd-Elshafy DN, Awad K, Bahgat MM.

Viral Immunol. 2020 Mar 23. doi: 10.1089/vim.2019.0163. [Epub ahead of print]

PMID:
32202987
2.

European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management.

Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, Seppänen MRJ, Sullivan KE, Jolles S.

J Clin Immunol. 2020 Feb 17. doi: 10.1007/s10875-020-00754-1. [Epub ahead of print]

PMID:
32064578
3.

Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis.

Shahini N, Ueland T, Auensen A, Michelsen AE, Ludviksen JK, Hussain AI, Pettersen KI, Aakhus S, Espeland T, Lunde IG, Kirschfink M, Nilsson PH, Mollnes TE, Gullestad L, Aukrust P, Yndestad A, Louwe MC.

J Immunol. 2019 Oct 1;203(7):1973-1980. doi: 10.4049/jimmunol.1801244. Epub 2019 Sep 6.

PMID:
31492744
4.

Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management.

Schröder-Braunstein J, Kirschfink M.

Mol Immunol. 2019 Oct;114:299-311. doi: 10.1016/j.molimm.2019.08.002. Epub 2019 Aug 14. Review.

PMID:
31421540
5.

C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.

Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C.

Front Immunol. 2019 May 31;10:1030. doi: 10.3389/fimmu.2019.01030. eCollection 2019.

6.

Increased compensatory kidney workload results in cellular damage in a short time porcine model of mixed acidemia - Is acidemia a 'first hit' in acute kidney injury?

Russ M, Ott S, Bedarf JR, Kirschfink M, Hiebl B, Unger JK.

PLoS One. 2019 Jun 17;14(6):e0218308. doi: 10.1371/journal.pone.0218308. eCollection 2019.

7.

Author Correction: Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties.

Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, Zipfel PF, Wallich R, Kraiczy P.

Sci Rep. 2019 May 2;9(1):7056. doi: 10.1038/s41598-019-42948-7.

8.

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Fishelson Z, Kirschfink M.

Front Immunol. 2019 Apr 10;10:752. doi: 10.3389/fimmu.2019.00752. eCollection 2019. Review.

9.

Immunological Alterations due to Hemodialysis Might Interfere with Early Complications in Renal Transplantation.

Mai K, Boldt A, Hau HM, Kirschfink M, Schiekofer S, Keller F, Beige J, Giannis A, Sack U, Rasche FM.

Anal Cell Pathol (Amst). 2019 Mar 25;2019:8389765. doi: 10.1155/2019/8389765. eCollection 2019.

10.

The Case | A 78-year-old woman with acute kidney injury and hemolytic anemia.

Zecher D, Banas B, Büttner-Herold M, Kirschfink M, Zipfel PF.

Kidney Int. 2019 Feb;95(2):473-474. doi: 10.1016/j.kint.2018.10.013. No abstract available.

PMID:
30665579
11.

Cisterno-lumbar gradient of complement fractions in geriatric patients with suspected normal pressure hydrocephalus.

Seele J, Kirschfink M, Djukic M, Lange P, Gossner J, Bunkowski S, Wiltfang J, Nau R.

Clin Chim Acta. 2018 Nov;486:1-7. doi: 10.1016/j.cca.2018.07.008. Epub 2018 Jul 10.

PMID:
30003878
12.

IgM cleavage by Streptococcus suis reduces IgM bound to the bacterial surface and is a novel complement evasion mechanism.

Rungelrath V, Weiße C, Schütze N, Müller U, Meurer M, Rohde M, Seele J, Valentin-Weigand P, Kirschfink M, Beineke A, Schrödl W, Bergmann R, Baums CG.

Virulence. 2018;9(1):1314-1337. doi: 10.1080/21505594.2018.1496778.

13.

Complement analysis in the era of targeted therapeutics.

Prohászka Z, Kirschfink M, Frazer-Abel A.

Mol Immunol. 2018 Oct;102:84-88. doi: 10.1016/j.molimm.2018.06.001. Epub 2018 Jun 20. Review.

PMID:
29933889
14.

Long-term Eculizumab Therapy in a Child With Refractory Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

Chanchlani R, Thorner P, Radhakrishnan S, Hebert D, Langlois V, Arora S, Barth D, Cattran D, Kirschfink M, Licht C.

Kidney Int Rep. 2017 Sep 8;3(2):482-485. doi: 10.1016/j.ekir.2017.08.019. eCollection 2018 Mar. No abstract available.

15.

A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.

Gallenkamp J, Spanier G, Wörle E, Englbrecht M, Kirschfink M, Greslechner R, Braun R, Schäfer N, Bauer RJ, Pauly D.

Oncotarget. 2017 Dec 6;9(3):3001-3013. doi: 10.18632/oncotarget.22963. eCollection 2018 Jan 9.

16.

Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.

Münch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C, Halbritter J.

Clin Kidney J. 2017 Dec;10(6):742-746. doi: 10.1093/ckj/sfx053. Epub 2017 Jul 10.

17.

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R.

Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.

PMID:
28366510
18.

Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties.

Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, Zipfel PF, Wallich R, Kraiczy P.

Sci Rep. 2017 Mar 22;7(1):303. doi: 10.1038/s41598-017-00412-4. Erratum in: Sci Rep. 2019 May 2;9(1):7056.

19.

Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S.

Pediatr Nephrol. 2017 Jun;32(6):1081-1087. doi: 10.1007/s00467-017-3612-9. Epub 2017 Feb 20. Review.

PMID:
28220235
20.

Local complement activation in aqueous humor in patients with age-related macular degeneration.

Schick T, Steinhauer M, Aslanidis A, Altay L, Karlstetter M, Langmann T, Kirschfink M, Fauser S.

Eye (Lond). 2017 May;31(5):810-813. doi: 10.1038/eye.2016.328. Epub 2017 Jan 27.

21.

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.

Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890. Epub 2016 Nov 25.

22.

Dissection of CD20 regulation in lymphoma using RNAi.

Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hüllein J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T.

Leukemia. 2016 Dec;30(12):2409-2412. doi: 10.1038/leu.2016.230. Epub 2016 Aug 18. No abstract available.

PMID:
27560109
23.

Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control.

Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M.

Immunobiology. 2016 Nov;221(11):1247-58. doi: 10.1016/j.imbio.2016.06.008. Epub 2016 Jul 18. Review.

PMID:
27475991
24.

Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.

Ahlenstiel-Grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L.

Nephrol Dial Transplant. 2016 Jul;31(7):1114-21. doi: 10.1093/ndt/gfw078. Epub 2016 May 4.

PMID:
27190382
25.

Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors.

Devarapu SK, Mamidi S, Plöger F, Dill O, Blixt O, Kirschfink M, Schwartz-Albiez R.

Int J Cancer. 2016 Jun 15;138(12):2963-73. doi: 10.1002/ijc.30025. Epub 2016 Feb 23.

26.

The complement system in cancer: Ambivalence between tumour destruction and promotion.

Mamidi S, Höne S, Kirschfink M.

Immunobiology. 2017 Jan;222(1):45-54. doi: 10.1016/j.imbio.2015.11.008. Epub 2015 Nov 28. Review.

PMID:
26686908
27.

Identification and characterization of a unique role for EDB fibronectin in phagocytosis.

Kraft S, Klemis V, Sens C, Lenhard T, Jacobi C, Samstag Y, Wabnitz G, Kirschfink M, Wallich R, Hänsch GM, Nakchbandi IA.

J Mol Med (Berl). 2016 May;94(5):567-81. doi: 10.1007/s00109-015-1373-0. Epub 2015 Dec 5.

28.

Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.

Mamidi S, Höne S, Teufel C, Sellner L, Zenz T, Kirschfink M.

Oncoimmunology. 2015 Jan 22;4(3):e979688. eCollection 2015 Mar.

29.

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT.

Pediatr Nephrol. 2015 Jun;30(6):1039-42. doi: 10.1007/s00467-015-3078-6. Epub 2015 Mar 10.

PMID:
25752761
30.

Association of history of allergies and influenza-like infections with laryngeal cancer in a case-control study.

Filippidis FT, Schwartz SM, Becker N, Dyckhoff G, Kirschfink M, Dietz A, Becher H, Ramroth H.

Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2063-9. doi: 10.1007/s00405-015-3528-6. Epub 2015 Jan 30.

PMID:
25634066
31.

Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.

Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, Schratzberger P, Lhotta K, Mayer G.

Medicine (Baltimore). 2014 Nov;93(26):e143. doi: 10.1097/MD.0000000000000143.

32.

Eculizumab hepatotoxicity in pediatric aHUS.

Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C.

Pediatr Nephrol. 2015 May;30(5):775-81. doi: 10.1007/s00467-014-2990-5. Epub 2014 Nov 22.

PMID:
25416628
33.

Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Cinci M, Mamidi S, Li W, Fehring V, Kirschfink M.

Target Oncol. 2015 Sep;10(3):405-13. doi: 10.1007/s11523-014-0345-6. Epub 2014 Nov 15.

PMID:
25395366
34.

Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.

Grumach AS, Kirschfink M.

Mol Immunol. 2014 Oct;61(2):110-7. doi: 10.1016/j.molimm.2014.06.030. Epub 2014 Jul 15. Review.

PMID:
25037634
35.

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.

Wehling C, Kirschfink M.

J Thromb Haemost. 2014 Sep;12(9):1437-9. doi: 10.1111/jth.12639. Epub 2014 Jul 15. No abstract available.

36.

Recurrent miscarriages, innate immunity, and autoimmune reaction to chlamydial 60-kDa heat shock protein--is there an association?

Eggert-Kruse W, Scholz S, Kirschfink M, Strowitzki T.

Fertil Steril. 2014 Jun;101(6):1675-80. doi: 10.1016/j.fertnstert.2014.02.048. Epub 2014 Mar 26.

PMID:
24680363
37.

Developing medical educators--a mixed method evaluation of a teaching education program.

Roos M, Kadmon M, Kirschfink M, Koch E, Jünger J, Strittmatter-Haubold V, Steiner T.

Med Educ Online. 2014 Mar 27;19:23868. doi: 10.3402/meo.v19.23868. eCollection 2014.

38.

Complement profile in neonates of different gestational ages.

Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M.

Scand J Immunol. 2014 Apr;79(4):276-81. doi: 10.1111/sji.12154.

39.

Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C.

Vasel M, Rutz R, Bersch C, Feick P, Singer MV, Kirschfink M, Nakchbandi IA.

Clin Immunol. 2014 Feb;150(2):149-56. doi: 10.1016/j.clim.2013.11.014. Epub 2013 Dec 5.

PMID:
24412908
40.

Complement factor H-related hybrid protein deregulates complement in dense deposit disease.

Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF.

J Clin Invest. 2014 Jan;124(1):145-55. doi: 10.1172/JCI71866. Epub 2013 Dec 16.

41.

Successful treatment of DEAP-HUS with eculizumab.

Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C.

Pediatr Nephrol. 2014 May;29(5):841-51. doi: 10.1007/s00467-013-2654-x. Epub 2013 Nov 20.

PMID:
24249282
42.

Impact of different types of resuscitation fluids on coagulation and continuous venovenous hemofiltration hemocompatibility in a porcine model.

Bedarf JR, Grosch-Ott S, Russ M, Wagner JJ, Hiebl B, Kirschfink M, Unger JK.

Ther Apher Dial. 2013 Oct;17(5):510-23. doi: 10.1111/1744-9987.12014. Epub 2013 Mar 1.

PMID:
24107280
43.

An international serum standard for application in assays to detect human complement activation products.

Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE.

Mol Immunol. 2013 Dec 15;56(3):232-9. doi: 10.1016/j.molimm.2013.05.221. Epub 2013 Jun 17. Review. Erratum in: Mol Immunol. 2014 Aug;60(2):115.

PMID:
23787367
44.

Pulp progenitor cell recruitment is selectively guided by a C5a gradient.

Chmilewsky F, Jeanneau C, Laurent P, Kirschfink M, About I.

J Dent Res. 2013 Jun;92(6):532-9. doi: 10.1177/0022034513487377. Epub 2013 Apr 19.

PMID:
23603337
45.

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.

Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M.

Mol Oncol. 2013 Jun;7(3):580-94. doi: 10.1016/j.molonc.2013.02.011. Epub 2013 Feb 20.

46.

The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition.

Wang H, Vinnikov I, Shahzad K, Bock F, Ranjan S, Wolter J, Kashif M, Oh J, Bierhaus A, Nawroth P, Kirschfink M, Conway EM, Madhusudhan T, Isermann B.

Thromb Haemost. 2012 Dec;108(6):1141-53. doi: 10.1160/TH12-07-0460. Epub 2012 Sep 26.

PMID:
23014597
47.

Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Liu L, Li W, Li Z, Kirschfink M.

Clin Exp Immunol. 2012 Aug;169(2):100-8. doi: 10.1111/j.1365-2249.2012.04596.x.

48.

Eculizumab and refractory membranoproliferative glomerulonephritis.

Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C.

N Engl J Med. 2012 Mar 22;366(12):1165-6. doi: 10.1056/NEJMc1106619. No abstract available.

PMID:
22435384
49.

Combined C3b and factor B autoantibodies and MPGN type II.

Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, Kirschfink M, Skerka C, Zipfel PF.

N Engl J Med. 2011 Dec 15;365(24):2340-2. doi: 10.1056/NEJMc1107484. No abstract available.

PMID:
22168663
50.

Remitting fever of unknown origin in a 20-year-old man.

Cinci M, Kirschfink M, Lorenz HM, Blank N.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):459-64. doi: 10.1002/acr.20666. No abstract available.

Supplemental Content

Loading ...
Support Center